Monitor upcoming share sales under the ATM program and shelf registration, which will likely lead to further dilution. The company's high cash burn rate suggests additional equity raises may be necessary, potentially pressuring the stock price.
Price Chart
Executive Summary
Corbus Pharmaceuticals filed an S-3 shelf registration, signaling potential future share issuance. The company recently raised $70.2 million in net proceeds from a November 2025 public offering and has sold additional shares under an ATM program. Despite raising capital, the company continues to burn cash, with net losses widening significantly year-over-year and cash reserves declining. This suggests ongoing dilution risk to fund operations.
Key Financial Metrics
Key Facts
- Company raised $70.2 million in net proceeds from a public offering completed November 3, 2025
- Net loss for nine months ended September 30, 2025 was $57.98 million, up from $30.68 million in the same period of 2024
- Cash and investments decreased from $149.1 million at year-end 2024 to $104.0 million at September 30, 2025
- Company has an active ATM program with $73.4 million remaining capacity as of September 30, 2025
- Research and development expenses more than doubled year-over-year, increasing from $23.4 million to $51.7 million for the nine-month period
Financial Impact
The company has burned approximately $45 million in cash over nine months while raising $73.1 million through equity offerings, indicating a high cash burn rate that will likely require continued dilutive financing
Risk Factors
- Continued high cash burn rate requiring additional dilutive financing
- Potential for significant shareholder dilution from future share issuances
- Failure to achieve clinical milestones could impact ability to raise future capital
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: 10-Q (2025-11-12) | 0001193125-25-277748 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | 8-K | $4.33 | awaiting T+60 | — | $3.99 (−7.85%) |
Sep 30, 2026 26d ago | SC 13G | $6.34 | awaiting T+60 | — | $3.99 (−37.07%) |
Sep 22, 2026 4w ago | Institutional Cluster | $7.88 | awaiting T+60 | — | $3.99 (−49.33%) |
Sep 14, 2026 6w ago | 8-K | $8.08 | awaiting T+60 | — | $3.99 (−50.62%) |
Sep 11, 2026 6w ago | Press Release | $8.08 | awaiting T+60 | — | $3.99 (−50.62%) |
Aug 12, 2026 10w ago | Insider Cluster | $10.08 | awaiting T+60 | — | $3.99 (−60.42%) |
Aug 10, 2026 11w ago | Insider Cluster | $9.51 | awaiting T+60 | — | $3.99 (−58.04%) |
May 26, 2026 21w ago | 8-K | $7.91 $9.99 | ▲ +26.30% | ▲ +23.57% | $3.99 (−49.56%) |
May 21, 2026 22w ago | 8-K | $11.51 $10.49 | ▼ −8.86% | ▼ −13.16% | $3.99 (−65.33%) |
May 14, 2026 23w ago | 8-K | $11.98 $9.46 | ▼ −21.04% | ▼ −24.62% | $3.99 (−66.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers